111 related articles for article (PubMed ID: 15779382)
1. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Tomono S; Uchiyama T; Ohyama Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
[No Abstract] [Full Text] [Related]
2. [Treatment for coronary artery disease patients with impaired glucose tolerance].
Kume A; Miyazaki T; Daida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
[No Abstract] [Full Text] [Related]
3. [Pathophysiological conditions progressing from impaired glucose tolerance: atherosclerosis].
Yokote K; Saito Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():250-4. PubMed ID: 15779381
[No Abstract] [Full Text] [Related]
4. [Impaired glucose tolerance in patients with ischemic heart diseases].
Yasuda S; Miyazaki S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():300-2. PubMed ID: 15779392
[No Abstract] [Full Text] [Related]
5. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Swanson A; Watrin K; Wilder L
J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
[TBL] [Abstract][Full Text] [Related]
6. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
7. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
8. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
9. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
10. [Pathophysiological conditions progressing from impaired glucose tolerance: stroke (cerebral infarction)].
Kiyohara Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():260-3. PubMed ID: 15779383
[No Abstract] [Full Text] [Related]
11. [Postprandial hypoglycemia].
Mori Y
Nihon Rinsho; 2006 Sep; Suppl 3():224-9. PubMed ID: 17022536
[No Abstract] [Full Text] [Related]
12. [Glucose intolerance: postprandial hyper glucose, risk factor for diabetic macroangiopathy].
Igarashi Y; Kawamori R
Nihon Rinsho; 2006 Nov; 64(11):1998-2004. PubMed ID: 17087289
[TBL] [Abstract][Full Text] [Related]
13. [The internal and external cohort studies about impaired glucose tolerance].
Shibazaki S; Nagai M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():82-6. PubMed ID: 15779350
[No Abstract] [Full Text] [Related]
14. [Early diagnosis of peripheral neuropathy in patients with impaired glucose tolerance (IGT)].
Yagihashi S
Nihon Rinsho; 2005 Jun; 63 Suppl 6():640-6. PubMed ID: 15999784
[No Abstract] [Full Text] [Related]
15. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
16. [Glinide(s), sulfonylurea(s)].
Arakawa M; Hirose T
Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
19. [Effect of impaired fasting glucose and impaired glucose tolerance on the progression of diabetic macroangiopathy].
Igarashi M; Tominaga M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():55-60. PubMed ID: 15779345
[No Abstract] [Full Text] [Related]
20. [IFG and IGT in Europe and America: the present and prospective].
Tsujii S; Kuzuya H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():27-33. PubMed ID: 15779341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
